Role of the eosinophil in the allergic reactions. I. EDI-an eosinophil-derived inhibitor of histamine release.
An inhibitor of histamine release was found to be associated with the human eosinophilic leukocyte. This eosinophil-derived inhibitor (EDI) was released from eosinophil-rich fractions upon sonication or interaction with immune reactants (specific allergens or anti-IgE). EDI was found to exert its inhibitory action at the target cell level by increasing the intracellular levels of cyclic-AMP. Preliminary electron microscopic studies show the presence of IgE on the eosinophilic leukocyte and it is suggested that the allergen or anti-IgE-induced release of EDI might be due to a direct interaction of these immune reactants with the eosinophil-bound IgE antibody. The results also suggest that by virtue of liberating a histamine release inhibitor such as EDI, the eopsinophil assumes a modulating role in the allergic inflammatory reaction.
D000818:Animals; D000906:Antibodies; D000937:Antigen-Antibody Reactions; D002469:Cell Separation; D000242:Cyclic AMP / Q000097:blood; D004804:Eosinophils / Q000276:immunology* / Q000648:ultrastructure; D005293:Ferritins; D005470:Fluorometry; D006041:Goats / Q000276:immunology; D006632:Histamine / Q000032:analysis; D006636:Histamine Release; D006801:Humans; D006967:Hypersensitivity / Q000276:immunology*; D007073:Immunoglobulin E; D007958:Leukocyte Count; D007962:Leukocytes / Q000032:analysis; D008854:Microscopy, Electron; D009504:Neutrophils / Q000276:immunology; D013010:Sonication; D014316:Tritium
D000906:Antibodies; D014316:Tritium; D007073:Immunoglobulin E; D006632:Histamine; D005293:Ferritins; D000242:Cyclic AMP